PARP1 and cancer: Defining the road from inhibiting PARP enzymatic activity to PARPi-induced cell death will be crucial to tackle the “holy trinity” in personalized cancer therapy28: deciding whom to treat based on biomarker-guided patient stratification, combating drug resistance by identifying mechanisms and predictive markers of reduced PARPi sensitivity, and optimizing combination therapy.